Bayer's Balancing Act: A $3 Billion Infusion Meets a $7.25 Billion Legal Crossroads

Bayer's Q2 core EPS fell 16.7% despite revenue growth; Apollo's €3B investment and $5B bond sale precede a pivotal September Roundup settlement hearing.

The arithmetic facing Bayer's leadership has rarely been starker. In the same quarter that the group's core earnings per share slid by nearly a fifth, management secured a €3 billion equity injection from Apollo Global Management and reaffirmed its full-year guidance. The juxtaposition captures the central tension of the company's current chapter: operational resilience is being built up on one side of the ledger, while a single courtroom date in Missouri threatens to redraw the other.

A Quarter of Contrasts

Bayer's second-quarter results, published ahead of the pivotal September hearing, showed a business that can still grow even as its bottom line compresses. Group revenue advanced 2.2 percent on a currency- and portfolio-adjusted basis to €10.872 billion, with the crop science division doing the heavy lifting. The unit's adjusted earnings jumped 30.2 percent, supported by firmer prices and lower manufacturing costs, helping lift adjusted EBITDA by 1.9 percent to €2.144 billion.

The picture dims further down the income statement. Core earnings per share fell 16.7 percent year on year to €0.95, a reminder that top-line momentum does not automatically translate into shareholder returns. Management nonetheless held its 2026 outlook steady, sticking with adjusted EBITDA guidance of €9.6 billion to €10.1 billion and core EPS of €4.20 to €4.70.

Apollo Deal and the Debt Dilemma

The balance sheet tells a more complicated story. Net financial debt climbed to €33.647 billion by June 30, roughly €2.6 billion above the year-end 2025 figure, even as the company narrowed its full-year debt target to €29–30 billion. The July agreement with Apollo is designed to bridge that gap: the asset manager takes a non-controlling minority stake in a newly formed entity housing Bayer's long-acting reversible contraception business—Mirena, Kyleena, and Jaydess—which generated €1.37 billion in sales last year. Bayer retains majority control and operational oversight, with closing expected in the third quarter.

That capital injection sits alongside earlier moves to shore up liquidity. In mid-July, Bayer placed $5 billion in US-dollar bonds across maturities ranging from five to thirty years. The debt raise expands financial headroom but also adds future interest obligations—a trade-off that becomes more consequential if the legal situation deteriorates.

The September Reckoning

All roads now lead to September 14, when a Missouri court is scheduled to hold the fairness hearing for the proposed $7.25 billion Roundup class settlement. The date was already pushed back once to accommodate claimants seeking to opt out following a US Supreme Court ruling. The central unknown is how many plaintiffs ultimately walk away—a figure that determines whether the settlement holds as structured or becomes more expensive than anticipated.

Analysts have responded to the quarterly numbers with cautious optimism. UBS lifted its price target to €62, Goldman Sachs to €63.50, and the DZ Bank set fair value at €60. The share price, however, has been less decisive: it slipped 1.4 percent to €48.32 in the most recent session, though it remains up 0.7 percent on the week. The stock has gained 31 percent since the start of the year and 73 percent over twelve months, leaving it roughly 10 percent below its 52-week high of €53.86—and about 88 percent above the year's trough of €25.78.

Pipeline Progress and Regulatory Tailwinds

Beyond the legal calendar, Bayer continues to build its pharmaceutical franchise. The May acquisition of Perfuse Therapeutics, valued at up to $2.45 billion including a $300 million upfront payment plus milestones, strengthens the ophthalmology portfolio. Regulatory advances add further momentum: Lynkuet received approval in the UK for hot flashes linked to breast cancer therapy, while Kerendia gained Chinese approval for heart failure.

The bull case rests on a straightforward proposition: if the court approves the settlement with a manageable opt-out rate, Bayer gains clarity on its largest overhang, and the operational improvements—double-digit growth at crop science, pipeline wins, and fresh capital—can drive the shares higher. The bear case is equally clear. A wave of opt-outs could unravel the settlement's math, and the nearly 20 percent drop in core EPS suggests operational gains are not yet reaching shareholders. Another postponement would signal that the post-Supreme Court legal landscape remains more treacherous than anticipated.

For now, the market is weighing a company that has strengthened its hand financially while standing on the edge of a legal verdict that could redefine its risk profile. The September hearing will determine which side of that equation prevails.